Techniques for health economics analysis in oncology: Part 2

Critical Reviews in Oncology/Hematology

Volumn 30, Issue 1, 1999, Pages 13-24

  Neymark, Niels ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH ECONOMICS; HOSPITAL COST; ONCOLOGY; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0033021999     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00027-4     Document Type: Article

References (24)

1. Neymark N. Techniques for health economic analysis in oncology. Part 1. CROH 1998.
2. Johannesson M, Jonsson B, Karlsson G Outcome measurement in economic evaluation. Health Econ. 5:1996;279-296.
3. Dranove D Measuring costs. Sloan F Valuing Health Care. 1995;Cambridge University Press, Cambridge.
4. Gold M, Russell L, Siegel J et al. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
5. Neymark N. Assessing the economic value of anti-cancer therapies. 1998;Springer, Heidelberg.
6. Sugden R, Williams A The Principles of Practical Cost-Benefit Analysis. 1978;Oxford University Press, Oxford.
7. Finkler S The distinction between costs and charges. Ann Int Med. 96:1982;102-109.
8. Drummond M, Stoddart G Economic analysis and clinical trials. Control Clin Trials. 5:1984;115-128.
9. Rittenhouse B, O'Brien B Threats to the validity of pharmacoeconomic analyses based on clinical trial data. Spilker B Quality of Life and Pharmacoeconomics in Clinical Trials. 1996;Lippincott-Raven, Philadelphia, PA.
10. Cook T, Campbell D Quasi-Experimentation: Design and Analysis Issues for Field Settings. 1979;Houghton Miffin, Boston.
11. Senn S Clinical trials and epidemiology. J Clin Epidemiol. 43:1991;628-632.
12. George S Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 14:1996;1364-1370.
13. Peto R, Collins R, Gray R Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol. 48:1995;23-40.
14. Brown M, Glick H, Harrell F, et al. Integrating economic analysis into cancer clinical trials: The NCI-ASCO Economics Workbook. Washington DC, 1997.
15. Fayers P, Hand DJ Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet. 350:1997;1025-1027.
16. Sculpher M, Drummond M, Buxton M. Economic evaluation in health care research and development: undertake it early and often. HERG Discussion paper No. 12. Uxbridge: Brunel University, 1995.
17. Sonnad SS, Foreman SE An incentive approach to physician implementation of medical practice guidelines. Health Econ. 6:1997;467-477.
18. ASCO: American Society of Clinical Oncology recommendations for the use of hematopoetic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-2508.
19. ASCO: Update of recommendations for the use of hematopoietic colonystimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957-60.
20. Grabowski H The effect of pharmacoeconomics on company research and development decisions. PharmacoEconomics. 11:1997;389-397.
21. Buxton M, O'Brien B Economic evaluation of ondansetron: preliminary analysis using clinical trial data prior to price setting. Br J Can. 66:1992;s64-s76.
22. DiMasi J, Hansen R, Grabowski H et al. The costs of innovation in the pharmaceutical industry. J Health Econ. 10:1991;107-142.
23. McGuire W, Neugut A, Arikian S et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol. 15:1997;640-645.
24. Johannesson M Theory and Methods of Economic Evaluation in Health Care. 1996;Kluwer, Dordrecht.